Belgium· BE-AMP-SAM520862-00

Miglustat Gen.Orph 100 mg

A miglustat product containing miglustat, registered in Belgium by Gen-Orph. The same ATC class is registered in 18 of our 19 countries.

ATC A16AX06

Checked against FAMHP / AFMPS (Belgium) on September 26, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about miglustatAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Miglustat is registered in 18 of 19 countries.

Countries holding a registration under ATC A16AX06 (miglustat), each read from that country’s own register.

This record: Belgium, from FAMHP / AFMPS (Belgium)
10 of them publish a price we can compare per daily dose

Search miglustat products by name

Miglustat · ATC A16AX06

18 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Germany
Icelandprice
Ireland
Italyprice
Japan
Netherlands
Norwayprice
Polandprice
Sweden
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of miglustat costs, country by country.

Normalised to the WHO defined daily dose (0.3 g), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Miglustat · price per daily dose (0.3 g)

USD · FX 28 Sept 2026

CH Switzerland$225.28

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)

Active substance: Miglustat
Manufacturer: Gen-Orph
Country: Belgium (BE)
ATC code: A16AX06
ATC class: Miglustat
Defined daily dose: 0.3 g, O
Reimbursed: Not published by this register
Source register: FAMHP / AFMPS (Belgium)
Last checked: September 26, 2026

Packs & prices · 3

be_apb
3704939
be_apb
7734379
be_apb
4516100

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

1 interaction on record for miglustat.

Graded by severity as the source publishes them — 1 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check miglustat against other medicines How interaction checks work

Miglustat · interactions on record

1 record

1 moderate

Most severe, free to view

ImigluceraseA16AB02moderate

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Miglustat in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All miglustat products

Authorised across Europe · EMA

The same active substance is authorised in 20 EEA countries. Names it is sold under:

Austria · Miglustat G.L.
Bulgaria · Миглустат G.L.
Cyprus · Miglustat Accord
Czechia · Miglustat Accord
Germany · Miglustat Accord, Miglustat Axunio
Denmark · Miglustat Bluefish, Miglustat Waymade
Spain · Miglustat Accord, Miglustat Waymade
Finland · Miglustat Accord, Miglustat Waymade
France · Miglustat Accord, Miglustat Bluefish
United Kingdom (Northern Ireland) · Miglustat Accord Healthcare, Miglustat Dipharma
Iceland · Miglustat Dipharma, Opfolda
Italy · Miglustat Accord, Miglustat Waymade
Liechtenstein · Miglustat Dipharma, Opfolda
Netherlands · Miglustat G.L., Miglustat Waymade
Norway · Miglustat Bluefish, Miglustat Dipharma
Poland · Miglustat, Miglustat Accord
Portugal · Miglustato Accord
Romania · Miglustat Accord
Sweden · Miglustat, Miglustat Bluefish
Slovakia · Miglustat Accord, Miglustat G.L. Pharma

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/f8fcf16c-1f33-443c-8f1d-7dc6485fa306
GET /v1/drugs/f8fcf16c-1f33-443c-8f1d-7dc6485fa306?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Miglustat Gen.Orph 100 mg",
  "name_fr": "Miglustat Gen.Orph 100 mg",
  "name_nl": "Miglustat Gen.Orph 100 mg",
  "amp_code": "SAM520862-00",
  "strengths": [
    "100.0000",
    "100.0000"
  ],
  "pack_count": 2,
  "substances": [
    "Miglustat",
    "Sodium Starch Glycolate (Type A)"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Miglustat",
  "authorisation_numbers": [
    "EU/1/17/1232/001",
    "EU/1/17/1232/002"
  ]
}

API reference MCP server Plans

See everything about miglustat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console